

## DEPARTMENT OF JUSTICE

## Antitrust Division

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on Advanced Combustion Catalyst and Aftertreatment Technologies—II**

Notice is hereby given that, on February 6, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Southwest Research Institute—Cooperative Research Group on Aftertreatment Technologies (“AC<sup>2</sup>AT-II”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identities of the parties to the venture are: Cummins, Inc., Columbus, IN; Denso Corporation, Aichi-ken, JAPAN; Isuzu, Tokyo, JAPAN; Komatsu Ltd., Tochigi-ken, JAPAN; and Weichai Power Co., Ltd., Weifang, PEOPLE’S REPUBLIC OF CHINA.

The general area of planned activities of AC<sup>2</sup>AT-II is to develop the most cost effective solutions for future engine systems by identifying and addressing the opportunities and challenges for integration of catalysts and aftertreatment systems to engines with advanced combustion technologies. The proposed program incorporates projects focused in four distinct areas: (1) Development of aftertreatment simulation tools; (2) low temperature catalyst design; (3) advanced aftertreatment system integration; and (4) catalyzed urea water solution (UWS).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit, Antitrust Division.*

[FR Doc. 2019–03534 Filed 2–27–19; 8:45 am]

**BILLING CODE 4410–11–P**

## DEPARTMENT OF JUSTICE

## Antitrust Division

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Interchangeable Virtual Instruments Foundation, Inc.**

Notice is hereby given that, on February 8, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Interchangeable Virtual Instruments Foundation, Inc. (“IVI Foundation”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Acqiris SA, Plan-les-Ouates, SWITZERLAND, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and IVI Foundation intends to file additional written notifications disclosing all changes in membership.

On May 29, 2001, IVI Foundation filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on July 30, 2001 (66 FR 39336).

The last notification was filed with the Department on June 14, 2018. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on July 9, 2018 (83 FR 31775).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit, Antitrust Division.*

[FR Doc. 2019–03529 Filed 2–27–19; 8:45 am]

**BILLING CODE 4410–11–P**

## DEPARTMENT OF JUSTICE

## Antitrust Division

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on CHEDE-VII**

Notice is hereby given that, on February 6, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Southwest Research Institute—

Cooperative Research Group on CHEDE-VII (“CHEDE-VII”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, A&D Technology, Inc., Ann Arbor, MI, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CHEDE-VII intends to file additional written notifications disclosing all changes in membership.

On January 6, 2016, CHEDE-VII filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on February 2, 2016 (81 FR 5484).

The last notification was filed with the Department on November 8, 2017. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on December 13, 2017 (82 FR 58653).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit, Antitrust Division.*

[FR Doc. 2019–03528 Filed 2–27–19; 8:45 am]

**BILLING CODE 4410–11–P**

## DEPARTMENT OF JUSTICE

## Antitrust Division

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium**

Notice is hereby given that, on January 28, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical CBRN Defense Consortium (“MCDCC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Altimmune, Inc., Gaithersburg, MD; Attogene Corp, Austin, TX; Autonomous Therapeutics, Inc., Brooklyn, NY; Government